VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 28, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that a Phase I human clinical trial has demonstrated that the company's second product AL-208 was safe and well-tolerated in 64 healthy and elderly adults. AL-208 is being developed as a treatment for the mild cognitive impairment that occurs following coronary artery bypass graft (MCI post-CABG) surgery, a market estimated at US$500-million for which there is no available treatment today.
